Healthcare / Medical DevicesStockholm
$0.23
-0.04 (-15.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-3.7M · quality 37.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-139.9%
↓Gross Margin
85.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-37.1%
FCF CAGR
—
FCF margin
-354.7%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.0M · net income $-10.2M · FCF $-10.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.0M | $3.0M | $11.0M | $17.5M | $12.2M |
| Net Income | $-10.2M | $-10.2M | $-5.1M | $-4.7M | $-12.1M |
| EBITDA | $-9.7M | $-9.7M | $-3.9M | $-2.6M | $-10.8M |
| EPS | -0.35 | -0.35 | -0.30 | -0.32 | -0.96 |
| Gross Margin | 85.0% | 85.0% | 91.5% | 79.8% | 79.1% |
| Operating Margin | -333.9% | -333.9% | -45.9% | -21.5% | -98.6% |
| Net Margin | -334.1% | -334.1% | -46.6% | -27.1% | -99.4% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.06 | 0.08 | 0.18 |
| Current Ratio | 3.39 | 3.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.8M | $-10.8M | $-2.9M | $-3.7M | $-12.0M |
| Returns | |||||
| ROE | -139.9% | -139.9% | -65.9% | -36.6% | -160.5% |
| Valuation | |||||
| P/B | 1.22 | 1.22 | 3.60 | 5.37 | 8.90 |
| Growth & Yield | |||||
| Revenue Growth | -72.5% | -72.5% | -36.9% | 43.5% | — |
| EPS Growth | -15.2% | -15.2% | 5.6% | 66.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-52.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.30 → -0.35
Residual
-52.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.